Mereo BioPharma is teaming up with Ultragenyx to work on its rare genetic bone disease drug. Worth $50 million upfront and with modest biobucks of up to $254 million on the table, the R&D collab and licensing deal focuses on setrusumab in osteogenesis imperfecta (OI), a rare genetic disorder marked by fragile bones and reduced bone mass resulting in bones that break easily, loose joints and weakened teeth.Source: Fierce Biotech 18/12/2020